Item 9 Labs Corp. CEO Sara Gullickson Recognized as Influential Cannabis Leader Named Among Women to Watch in 2019

SCOTTSDALE, Ariz., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Sara Gullickson, CEO of Item 9 Labs Corp. (INLB), recently was selected by Marijuana Business Magazine for its Women to Watch in 2019 list. Covering the international cannabis market, the 22 featured women were recognized as preeminent leaders who merit attention in the New Year.

Gullickson was highlighted as an intrepid entrepreneur who established her own cannabis consulting firm Dispensary Permits at age 26. She now serves as CEO of publicly traded company Item 9 Labs, a leading developer and manufacturer of innovative cannabis products.

In her Women to Watch interview, Gullickson provided advice for those interested in entering the market, “Slow and steady wins the race. I see so many people trying to get rich quick. If you work hard, remain dedicated to your core values and make savvy business decisions, profits will follow.”

Item 9 Labs operates an indoor cultivation facility zoned on 50 acres in Arizona. Under Gullickson’s leadership, Item 9 Labs will serve as a parent company for multiple brands, including Dispensary Permits and Dispensary Templates, as well as the management of Strive Wellness of Nevada, a cultivation, processing, and distribution facility in Nevada.

This week, Item 9 Labs was featured in an Arizona Republic article showcasing the top companies in the state’s booming medical marijuana program. Item 9 Labs is currently in the final stages of completing a 10,000 square-foot expansion that will double the size of its Arizona facility.

“We are one of the fastest growing cities in the country. Our patient base is very healthy … and the licenses from the business model standpoint are very high-valued. Arizona is attractive to out-of-state groups because you get full vertical integration,” Gullickson stated in her interview with the Republic.

As CEO of the rapidly growing venture, Gullickson’s goal for 2019 is to acquire additional marijuana licenses in up to ten markets, including: Arizona, California, Nevada, New Jersey, New York, North Dakota, Ohio, Oregon, Pennsylvania, and Washington state.

For information visit Item9LabsCorp.com.

About Item 9 Labs Corp.:
Item 9 Labs Corp. (INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.

Forward-Looking Statement: 
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Neko Catanzaro
Proven Media
[email protected]
(401)-484-4980

Investor Contact:
Jeffrey Rassas